Together, these results emphasize the antileukemic potential of p53 re-engagement by idasanutlin as a therapeutic strategy against a broad range of ALL subtypes harboring wildtype TP53 at concentrations well-below clinically attainable levels. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.